-DOCSTART- -X- O
Ebola -X- _ B-Patient
virus -X- _ I-Patient
infection -X- _ I-Patient
can -X- _ O
cause -X- _ O
severe -X- _ O
hemorrhagic -X- _ O
fever -X- _ O
with -X- _ O
a -X- _ O
high -X- _ O
mortality -X- _ O
in -X- _ O
humans. -X- _ O
The -X- _ O
outbreaks -X- _ O
of -X- _ O
Ebola -X- _ O
viruses -X- _ O
in -X- _ O
2014 -X- _ O
represented -X- _ O
the -X- _ O
most -X- _ O
serious -X- _ O
Ebola -X- _ O
epidemics -X- _ O
in -X- _ O
history -X- _ O
and -X- _ O
greatly -X- _ O
threatened -X- _ O
public -X- _ O
health -X- _ O
worldwide. -X- _ O
The -X- _ O
development -X- _ O
of -X- _ O
additional -X- _ O
effective -X- _ O
anti-Ebola -X- _ B-Intervention
therapeutic -X- _ I-Intervention
agents -X- _ I-Intervention
is -X- _ O
therefore -X- _ O
quite -X- _ O
urgent. -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
via -X- _ O
high -X- _ O
throughput -X- _ O
screening -X- _ O
of -X- _ O
Food -X- _ O
and -X- _ O
Drug -X- _ O
Administration-approved -X- _ O
drugs -X- _ O
, -X- _ O
we -X- _ O
identified -X- _ O
that -X- _ O
teicoplanin -X- _ B-Intervention
, -X- _ I-Intervention
a -X- _ I-Intervention
glycopeptide -X- _ I-Intervention
antibiotic -X- _ I-Intervention
, -X- _ O
potently -X- _ O
prevents -X- _ B-Outcome
the -X- _ I-Outcome
entry -X- _ I-Outcome
of -X- _ I-Outcome
Ebola -X- _ I-Outcome
envelope -X- _ I-Outcome
pseudotyped -X- _ I-Outcome
viruses -X- _ I-Outcome
into -X- _ I-Outcome
the -X- _ I-Outcome
cytoplasm. -X- _ I-Outcome
Furthermore -X- _ O
, -X- _ O
teicoplanin -X- _ B-Intervention
also -X- _ O
has -X- _ O
an -X- _ O
inhibitory -X- _ B-Outcome
effect -X- _ I-Outcome
on -X- _ I-Outcome
transcription- -X- _ I-Outcome
and -X- _ I-Outcome
replication-competent -X- _ I-Outcome
virus-like -X- _ I-Outcome
particles -X- _ I-Outcome
, -X- _ I-Outcome
with -X- _ I-Outcome
an -X- _ I-Outcome
IC -X- _ I-Outcome
( -X- _ I-Outcome
50 -X- _ I-Outcome
) -X- _ I-Outcome
as -X- _ I-Outcome
low -X- _ I-Outcome
as -X- _ I-Outcome
330 -X- _ I-Outcome
nm. -X- _ I-Outcome
Comparative -X- _ O
analysis -X- _ O
further -X- _ O
demonstrated -X- _ O
that -X- _ O
teicoplanin -X- _ B-Intervention
is -X- _ O
able -X- _ O
to -X- _ O
block -X- _ B-Outcome
the -X- _ I-Outcome
entry -X- _ I-Outcome
of -X- _ I-Outcome
Middle -X- _ I-Outcome
East -X- _ I-Outcome
respiratory -X- _ I-Outcome
syndrome -X- _ I-Outcome
( -X- _ I-Outcome
MERS -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
severe -X- _ I-Outcome
acute -X- _ I-Outcome
respiratory -X- _ I-Outcome
syndrome -X- _ I-Outcome
( -X- _ I-Outcome
SARS -X- _ I-Outcome
) -X- _ I-Outcome
envelope -X- _ I-Outcome
pseudotyped -X- _ I-Outcome
viruses -X- _ I-Outcome
as -X- _ I-Outcome
well. -X- _ I-Outcome
Teicoplanin -X- _ B-Intervention
derivatives -X- _ O
such -X- _ O
as -X- _ O
dalbavancin -X- _ B-Intervention
, -X- _ I-Intervention
oritavancin -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
telavancin -X- _ I-Intervention
can -X- _ O
also -X- _ O
inhibit -X- _ O
the -X- _ O
entry -X- _ O
of -X- _ O
Ebola -X- _ O
, -X- _ O
MERS -X- _ O
, -X- _ O
and -X- _ O
SARS -X- _ O
viruses. -X- _ O
Mechanistic -X- _ O
studies -X- _ O
showed -X- _ O
that -X- _ O
teicoplanin -X- _ O
blocks -X- _ B-Outcome
Ebola -X- _ I-Outcome
virus -X- _ I-Outcome
entry -X- _ I-Outcome
by -X- _ I-Outcome
specifically -X- _ I-Outcome
inhibiting -X- _ I-Outcome
the -X- _ I-Outcome
activity -X- _ I-Outcome
of -X- _ I-Outcome
cathepsin -X- _ I-Outcome
L -X- _ I-Outcome
, -X- _ O
opening -X- _ O
a -X- _ O
novel -X- _ O
avenue -X- _ O
for -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
additional -X- _ O
glycopeptides -X- _ O
as -X- _ O
potential -X- _ O
inhibitors -X- _ O
of -X- _ O
cathepsin -X- _ O
L-dependent -X- _ O
viruses. -X- _ O
Notably -X- _ O
, -X- _ O
given -X- _ O
that -X- _ O
teicoplanin -X- _ B-Intervention
has -X- _ O
routinely -X- _ O
been -X- _ O
used -X- _ O
in -X- _ O
the -X- _ O
clinic -X- _ O
with -X- _ O
low -X- _ O
toxicity -X- _ O
, -X- _ O
our -X- _ O
work -X- _ O
provides -X- _ O
a -X- _ O
promising -X- _ O
prospect -X- _ O
for -X- _ O
the -X- _ O
prophylaxis -X- _ O
and -X- _ O
treatment -X- _ O
of -X- _ O
Ebola -X- _ O
, -X- _ O
MERS -X- _ O
, -X- _ O
and -X- _ O
SARS -X- _ O
virus -X- _ O
infection -X- _ O
. -X- _ O

